

JYNARQUE® (tolvaptan) REMS PRESCRIBER KNOWLEDGE ASSESSMENT

To become a certified prescriber in the JYNARQUE REMS, you must: complete this *Prescriber Knowledge Assessment* and the *Prescriber Enrollment Form*. You must answer ALL eight questions correctly to become certified.

1. Review the following materials:

- *Prescribing Information*
- *REMS Program Overview*
- *Prescriber Training*

2. Complete your name, NPI number and phone number and answer all 8 questions

3. Submit your completed *Prescriber Knowledge Assessment* and *Prescriber Enrollment Form* to the REMS online at www.JYNARQUErems.com or via fax at 1-866-750-6820

If completed via fax, you will be notified by the REMS on the status of your certification within 2 business days upon receipt. When contacted, you will receive either:

- Confirmation of your certification in the REMS or
- Instructions on how to retake the *Prescriber Knowledge Assessment*, if necessary

*Indicates required field

Prescriber Information

First Name*: _____ Middle Initial: _____ Last Name*: _____
National Provider Identifier No. (NPI)*: _____ Phone*: _____
Email: _____

Questions 1 – 8 Select the 1 best answer

Question 1

Before starting a new patient on JYNARQUE, I should

- Read the U.S. **Prescribing Information** (USPI), **Prescriber Training**, and the **REMS Program Overview**
- Counsel patients about the risk of serious and potentially fatal liver injury associated with JYNARQUE
- Order and review baseline hepatic labs
- All of the above

Question 2

Patients you identify as appropriate for JYNARQUE must enroll in the JYNARQUE REMS Program in order to be able to receive treatment True False

Question 3

JYNARQUE is indicated to slow kidney function decline in adults at risk of rapidly progressing autosomal dominant polycystic kidney disease (ADPKD). True False

Question 4

The primary counseling message I should tell my patients is:

- Do not drink alcohol before you take JYNARQUE
- Stop therapy if ALT or AST is >2 times the ULN
- There is a risk of serious and potentially fatal liver injury associated with JYNARQUE and that blood testing and monitoring is required
- Patients need to have blood tests every 18 months

Question 5

I will submit a **Patient Status Form** for each patient every 3 months for first 18 months of treatment and every 6 months thereafter. True False

Question 6

I will educate my patients on JYNARQUE; the REMS; and the signs and symptoms of liver injury and what to do should they experience them, before I enroll them into the REMS. True False

Question 7

Patients can take JYNARQUE and elect not to have blood tests done. True False

Question 8

Only pharmacies enrolled in the REMS may dispense JYNARQUE to patients. True False

Phone: 1-866-244-9446 | www.JYNARQUErems.com | Fax: 1-866-750-6820

Healthcare providers must report cases of liver injury to the REMS Program Coordinating Center.

JYNARQUE®
(tolvaptan) tablets



Otsuka

Otsuka America Pharmaceutical, Inc.

Manufactured by Otsuka Pharmaceutical Co., Ltd., Tokyo, 101-8535 Japan.

Distributed and marketed by Otsuka America Pharmaceutical, Inc., Rockville, MD 20850 USA.

JYNARQUE is a registered trademark of Otsuka Pharmaceutical Co., Ltd., Tokyo, 101-8535 Japan.

©2019 Otsuka America Pharmaceutical, Inc.

[Month Year of Approval]

XXXXXXXXXXXX

JYNARQUE[®]
(tolvaptan) tablets